Wormiza 444 mg Tablet is a veterinary medication containing fenbendazole, an anthelmintic commonly used to treat parasitic worm infections in animals. While fenbendazole is widely used in veterinary medicine, its safety and approval for human use remain limited and controversial. Currently, Wormiza 444 mg is not approved by regulatory authorities such as the FDA for use in humans.

Fenbendazole works by disrupting the parasite’s cellular structure, ultimately killing the worms. Some anecdotal reports and preliminary studies have sparked interest in its potential off-label use in humans, including experimental applications for parasitic infections and even cancer treatment. However, these uses have not been rigorously studied in clinical trials, and the drug’s safety profile for humans is not well established.

Potential side effects of fenbendazole in humans may include nausea, abdominal pain, headache, and allergic reactions. There is also a risk of drug interactions with other medications. Because Wormiza 444 mg is formulated for animals, the dosage and excipients may not be suitable for human consumption.

In summary, Wormiza 444 mg should not be used in humans without medical supervision. Anyone considering fenbendazole for human use must consult a qualified healthcare professional to understand the risks and receive appropriate guidance. Safety and efficacy for humans remain areas requiring further scientific research.